In this article, we will look at the 13 Best Large Cap Stocks to Invest in For the Long Term.
On November 20, Warren Pies, 3Fourteen Research, appeared on CNBC’s ‘Closing Bell’ to talk about the market fundamentals and his opinion on the equity markets.
Pies does not see anything fundamentally broken in today’s markets and stated that if we go through our checklist, we can see that a recession does not seem imminent. While there is some slowness and the labor market is a point of pain, the Fed is addressing that. In addition, 60% of the S&P 500 companies are reporting positive results, which is in the top 30 percentile historically and not what you typically see when entering a recession.
READ ALSO: 13 Cheap Stocks Under $10 to Buy Now and 14 Best Undervalued Stocks to Buy Under $50.
What the market did have, according to him, was sentiment, which was off the charts extreme optimism as we came through the summer months. Additionally, we did not have any pullbacks, the first pullback of 3% in 137 trading days, which he called a “crazy long streak”. Breaking that streak feels scary for a lot of people, according to Pies, but he just considers it a sentiment reset.
With these trends in view, let’s look at the best large cap stocks to invest in for the long term.
Our Methodology
We used Finviz and cross checked stocks across ETFs and rankings of long term stocks to compile a list of top large cap stocks with a 5-year revenue growth above 10% and positive analyst sentiment. We then selected the top 13 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on November 21.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13 Best Large Cap Stocks to Invest in For the Long Term
13. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
5-Year Revenue Growth: 14.37%
Analyst Upside: 11.11%
Market Cap: $107.15 billion
Number of Hedge Fund Holders: 53
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) received Hold ratings from Maxim Group analyst Naz Rehman on November 11 and Needham’s Joseph Stringer on November 10.
The rating updates followed the company’s announcement on November 8 concerning the updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported that the 48-week data reflected a 64% drop from aseline in proteinuria in IgA nephropathy, along with an “82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases”.
Pove is an “investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines”, and is the only BAFF+APRIL inhibitor in pivotal trials for several kidney diseases.
Management further reported that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is on the path to initiate rolling submission of a Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare, serious diseases. Its four approved medicines treat cystic fibrosis (CF), and one approved therapy treats severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company’s product pipeline includes clinical-stage programs for various disorders, including TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency.
12. CrowdStrike Holdings, Inc. (NASDAQ:CRWD)
5-Year Revenue Growth: 46.01%
Analyst Upside: 3.04%
Market Cap: $125.81 billion
Number of Hedge Fund Holders: 66
CrowdStrike Holdings, Inc. (NASDAQ:CRWD) is one of the best large cap stocks to invest in for the long term. On November 21, Oppenheimer lifted the price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $580 from $560 while maintaining an Outperform rating on the shares. The firm supported the optimistic rating with the positive October-end checks for the company, stating that it showed the fourth consecutive quarter of partners tracking above plan.
Separately, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced a major global partnership with CoreWeave, The Essential Cloud for AI™, on November 5, focused on securing an AI cloud foundation for the agentic era and accelerating the “march” towards secure AGI.
Management reported that the collaboration combines CrowdStrike Falcon® platform’s protection and CoreWeave’s high-performance AI Cloud to “secure and accelerate the complex computing workloads that drive modern AI innovation – protecting the systems where intelligence is built, trained, and deployed”. The collaboration empowers AI pioneers for faster and more confident innovation on infrastructure secured by design.
CrowdStrike Holdings, Inc. (NASDAQ:CRWD) offers cybersecurity services and products to prevent breaches. Its offerings include cloud-delivered protection across endpoints, threat hunting, managed security services, IT operations management, log management, and more.
